$KIDS
OrthoPediatrics Corp Stock $kids

$kids Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000142545020000043 Filed on May 06, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019 Q1
Revenue	$16.36M	$18.95M	$14.66M
YoY Change	11.6%	30.09%	21.18%
Cost Of Revenue	$4.143M	$4.500M	$4.001M
YoY Change	3.55%	11.11%	26.02%
Gross Profit	$12.21M	$14.45M	$10.66M
YoY Change	14.62%	37.44%	19.46%
Gross Profit Margin	74.67%	76.25%	72.7%
Selling, General & Admin	$15.45M	$15.58M	$12.16M
YoY Change	27.03%	40.36%	0.52%
% of Gross Profit	126.46%	107.82%	114.12%
Research & Development	$1.265M	$1.910M	$1.213M
YoY Change	4.29%	49.22%	-0.41%
% of Gross Profit	10.36%	13.22%	11.38%
Depreciation & Amortization	$1.375M	$1.410M	$828.0K
YoY Change	66.06%	98.59%	21.59%
% of Gross Profit	11.26%	9.76%	7.77%
Operating Expenses	$16.71M	$17.48M	$13.37M
YoY Change	24.96%	41.2%	0.44%
Operating Profit	-$4.497M	-$3.031M	-$2.717M
YoY Change	65.51%	62.43%	-38.18%
Interest Expense	-$380.0K	-$1.310M	-$300.0K
YoY Change	26.67%	147.17%	-45.45%
% of Operating Profit
Other Income/Expense, Net	-$448.0K	$10.00K	-$303.0K
YoY Change	47.85%	-114.29%	-49.92%
Pretax Income	-$4.945M	-$4.329M	-$3.020M
YoY Change	63.74%	75.26%	-39.6%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$4.945M	-$5.429M	-$3.020M
YoY Change	63.74%	119.98%	-39.6%
Net Earnings / Revenue	-30.23%	-28.65%	-20.61%
Basic Earnings Per Share	-$0.30
Diluted Earnings Per Share	-$0.30	-$361.0K	-$210.2K
COMMON SHARES
Basic Shares Outstanding	16.42M shares	14.97M shares	14.54M shares
Diluted Shares Outstanding	16.42M shares

Balance Sheet

Concept	2020 Q1	2019 Q4	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$53.60M	$70.80M	$52.80M
YoY Change	1.52%	16.64%	52.6%
Cash & Equivalents	$53.58M	$70.78M	$52.77M
Short-Term Investments
Other Short-Term Assets	$2.900M	$2.800M	$1.500M
YoY Change	93.33%	115.38%	36.36%
Inventory	$43.97M	$38.00M	$28.08M
Prepaid Expenses
Receivables	$14.12M	$16.00M	$10.30M
Other Receivables	$600.0K	$600.0K	$500.0K
Total Short-Term Assets	$115.1M	$128.1M	$93.11M
YoY Change	23.64%	31.81%	41.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.08M	$21.35M	$16.79M
YoY Change	43.42%	67.21%	36.72%
Goodwill	$15.18M	$13.77M
YoY Change
Intangibles			$2.106M
YoY Change			-12.76%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$59.08M	$54.10M	$18.90M
YoY Change	212.66%	2380.33%	28.59%
TOTAL ASSETS
Total Short-Term Assets	$115.1M	$128.1M	$93.11M
Total Long-Term Assets	$59.08M	$54.10M	$18.90M
Total Assets	$174.2M	$182.2M	$112.0M
YoY Change	55.53%	62.49%	38.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.262M	$6.467M	$6.344M
YoY Change	30.23%	62.86%	-11.85%
Accrued Expenses	$3.000M	$4.300M	$2.700M
YoY Change	11.11%	19.44%	17.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$126.0K	$124.0K	$120.0K
YoY Change	5.0%	5.08%	5.26%
Total Short-Term Liabilities	$13.83M	$13.66M	$10.82M
YoY Change	27.8%	48.24%	2.39%
LONG-TERM LIABILITIES
Long-Term Debt	$21.04M	$26.07M	$21.13M
YoY Change	-0.43%	23.21%	-16.53%
Other Long-Term Liabilities	$57.00K	$63.00K
YoY Change
Total Long-Term Liabilities	$21.10M	$26.13M	$21.13M
YoY Change	-0.16%	23.51%	-16.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.83M	$13.66M	$10.82M
Total Long-Term Liabilities	$21.10M	$26.13M	$21.13M
Total Liabilities	$34.93M	$39.79M	$31.96M
YoY Change	9.31%	31.01%	-10.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.8M	-$128.8M	-$118.1M
YoY Change	13.26%	11.93%	9.3%
Common Stock	$4.000K	$4.000K	$4.000K
YoY Change	0.0%	0.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$187.0K	$0.00
YoY Change
Treasury Stock Shares	4.014K shares	0.000 shares
Shareholders Equity	$139.3M	$142.4M	$80.05M
YoY Change
Total Liabilities & Shareholders Equity	$174.2M	$182.2M	$112.0M
YoY Change	55.53%	62.49%	38.89%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019 Q1
OPERATING ACTIVITIES
Net Income	-$4.945M	-$5.429M	-$3.020M
YoY Change	63.74%	119.98%	-39.6%
Depreciation, Depletion And Amortization	$1.375M	$1.410M	$828.0K
YoY Change	66.06%	98.59%	21.59%
Cash From Operating Activities	-$6.956M	-$6.930M	-$3.471M
YoY Change	100.4%	154.78%	-31.04%
INVESTING ACTIVITIES
Capital Expenditures	$3.953M	-$1.380M	$4.963M
YoY Change	-20.35%	-2860.0%	79.11%
Acquisitions	$1.670M		$0.00
YoY Change
Other Investing Activities	-$1.670M	-$150.0K
YoY Change		-70.0%
Cash From Investing Activities	-$5.623M	-$1.530M	-$4.982M
YoY Change	12.87%	232.61%	70.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$187.0K		$0.00
YoY Change
Debt Paid & Issued, Net			$29.00K
YoY Change			3.57%
Cash From Financing Activities	-$4.530M	59.97M	$536.0K
YoY Change	-945.15%	52.13%	-2014.29%
NET CHANGE
Cash From Operating Activities	-$6.956M	-6.930M	-$3.471M
Cash From Investing Activities	-$5.623M	-1.530M	-$4.982M
Cash From Financing Activities	-$4.530M	59.97M	$536.0K
Net Change In Cash	-$17.09M	51.51M	-$7.917M
YoY Change	115.81%	42.14%	-0.93%
FREE CASH FLOW
Cash From Operating Activities	-$6.956M	-$6.930M	-$3.471M
Capital Expenditures	$3.953M	-$1.380M	$4.963M
Free Cash Flow	-$10.91M	-$5.550M	-$8.434M
YoY Change	29.35%	100.36%	8.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity File Number EntityFileNumber	001-38242
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001425450
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	kids	Classof Warrantor Right Term ClassofWarrantorRightTerm	P10Y
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	OrthoPediatrics Corp
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1761833
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	2850 Frontier Drive
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Warsaw
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53580000	USD
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46582
CY2020Q1	dei	City Area Code CityAreaCode	574
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	268-6379
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00025 par value per share
CY2020Q1	dei	Trading Symbol TradingSymbol	KIDS
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2020Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17818443	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70777000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	1361000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1250000	USD
CY2020Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	176000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	506000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14118000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16003000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	43966000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	38000000	USD
CY2020Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	582000	USD
CY2019Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	564000	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1514000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1464000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	115121000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	128058000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24078000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21349000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	15121000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14484000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	15179000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	13773000	USD
CY2020Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4700000	USD
CY2019Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	4490000	USD
CY2020Q1	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	35000000	USD
CY2019Q4	kids	Assets Noncurrent Excluding Property Plant And Equipment AssetsNoncurrentExcludingPropertyPlantAndEquipment	32747000	USD
CY2020Q1	us-gaap	Assets Assets	174199000	USD
CY2019Q4	us-gaap	Assets Assets	182154000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8262000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6467000	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2977000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4349000	USD
CY2020Q1	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	126000	USD
CY2019Q4	kids	Long Term Debt Current Maturities Related Party LongTermDebtCurrentMaturitiesRelatedParty	124000	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2467000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2723000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13832000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13663000	USD
CY2020Q1	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	21043000	USD
CY2019Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	26067000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	63000	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	21100000	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	26130000	USD
CY2020Q1	us-gaap	Liabilities Liabilities	34932000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	39793000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00025
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16887674	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16887674	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16723128	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16723128	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	274578000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	271182000	USD
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	4014	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	187000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133767000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128822000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1361000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	139267000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	142361000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	174199000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	182154000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16356000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14656000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4143000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4001000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	12213000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	10655000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7564000	USD
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6547000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7881000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5612000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1265000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	16710000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	13372000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1213000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4497000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2717000	USD
CY2020Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-379000	USD
CY2019Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-303000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-69000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-448000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-303000	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4945000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3020000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3020000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16423853	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14367056	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4945000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1358000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	301000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1358000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6303000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2719000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	142361000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4945000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1358000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	688000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	958000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1750000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	187000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	139267000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	81732000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3020000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	301000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	565000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	471000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	80049000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4945000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1375000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	828000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	958000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	471000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	-760000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts And Notes Receivable IncreaseDecreaseInAccountsAndNotesReceivable	1180000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5096000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2156000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	196000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1739000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2373000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1694000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-719000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-3000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-128000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6956000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3471000	USD
CY2020Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1670000	USD
CY2019Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3953000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4963000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5623000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4982000	USD
CY2020Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
CY2019Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	187000	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	688000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	565000	USD
CY2020Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	31000	USD
CY2019Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	29000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4530000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	536000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2020Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17086000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7917000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72027000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60691000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54941000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52774000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	379000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	303000	USD
CY2020Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	182000	USD
CY2019Q1	kids	Transfer Of Property And Equipment To Inventory TransferOfPropertyAndEquipmentToInventory	217000	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	1750000	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	BUSINESS<div style="padding-right:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">OrthoPediatrics Corp., a Delaware corporation, is a medical device company committed to designing, developing and marketing anatomically appropriate implants and devices for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. We sell our specialized products, including PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, PediPlates</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, Cannulated Screws, PediFlex</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">nail, PediNail</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;vertical-align:top;">TM</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;">, PediLoc</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:121%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;"> Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform \| Femur, Orthex, and QuickPack</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-weight:400;line-height:121%;vertical-align:top;">TM, </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:121%;"> to various hospitals and medical facilities throughout the United States and various international markets. We currently use a contract manufacturing model for the manufacturing of implants and related surgical instrumentation. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In 2017, we expanded operations and established legal entities in the United Kingdom, Australia and New Zealand, permitting us to sell under an agency model direct to local hospitals in these countries. In September 2018, we further expanded operations in Canada selling direct to local hospitals, and in January 2019 we expanded to Belgium and the Netherlands. Additionally, in March 2019 we established a holding company and an operating company in the Netherlands and began selling direct to Italy in March 2020 enhancing our operations in Europe. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On June 4, 2019, we purchased all the issued and outstanding shares of stock of Vilex in Tennessee, Inc. ("Vilex") and all the issued and outstanding units of membership interests in Orthex, LLC ("Orthex") for $60,000 in total consideration. Vilex and Orthex (the "Vilex Companies") are primarily manufacturers of foot and ankle surgical implants, including cannulated screws, fusion devices, surgical staples and bone plates, as well as Orthex Hexapod technology which is used to treat pediatrics congenital deformities and limb length discrepancies.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 31, 2019, we divested substantially all of the assets relating to Vilex's adult product offerings to a wholly-owned subsidiary of Squadron Capital LLC ("Squadron") in exchange for a $25,000 reduction in a Term Note owed to Squadron in connection with the initial acquisition. As part of the sale, we also executed an exclusive license arrangement with Squadron providing for perpetual access to certain intellectual property and a mutual distribution agreement. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 9, 2020, we purchased all the issued and outstanding membership interest of Telos Partners, LLC ("Telos") for $3,500 in total consideration. Telos is a boutique regulatory consulting firm formed in Colorado. </span></div>Our largest investor is Squadron, a private investment firm based in Granby, Connecticut.
CY2019Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133767000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-128822000	USD
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesPreparation of the condensed consolidated financial statements requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as of the date of the condensed consolidated financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. The impact of the coronavirus disease ("COVID-19") has significantly increased economic and demand uncertainty. We use historical experience and other assumptions as the basis for our judgments and estimates. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the condensed consolidated financial statements.
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q2	us-gaap	Business Acquisition Share Price BusinessAcquisitionSharePrice	40.76
CY2019Q2	kids	Business Combination Escrow Deposit Maximum Term BusinessCombinationEscrowDepositMaximumTerm	P20M
CY2020Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	737000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	0	USD
CY2019	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	3397000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	13773000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	15179000	USD
CY2020Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	21169000	USD
CY2019Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	26191000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	126000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	124000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	21043000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	26067000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	260000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitation	16200000	USD
CY2014Q2	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	1062000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimit	9736000	USD
CY2018Q4	kids	Operating Loss Carryforwards Limitationson Use Estimated Amount Subjectto Limitation Annual Limit Increase OperatingLossCarryforwardsLimitationsonUseEstimatedAmountSubjecttoLimitationAnnualLimitIncrease	22430000	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	70628	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.97
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y2M12D
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	22208	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	30.97
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	48420	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.97
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y2M12D
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	958000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	471000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	404	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	404	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.97
CY2020Q1	kids	Classof Warrantor Right Exercised ClassofWarrantorRightExercised	0	shares
CY2020Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	4014	shares
CY2020Q1	us-gaap	Treasury Stock Carrying Basis TreasuryStockCarryingBasis	187000	USD
CY2020Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	46.51
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4945000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3020000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16423853	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14367056	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	464536	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	403269	shares
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16356000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14656000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16356000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14656000	USD
CY2020Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	57000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	58000	USD
CY2020Q1	kids	Researchand Development Arrangement Contractto Performfor Others Minimum Annual Royalty Payment ResearchandDevelopmentArrangementContracttoPerformforOthersMinimumAnnualRoyaltyPayment	500000	USD

Files In Submission

Name	View Source	Status
0001425450-20-000043-index-headers.html	Edgar Link	pending
0001425450-20-000043-index.html	Edgar Link	pending
0001425450-20-000043.txt	Edgar Link	pending
0001425450-20-000043-xbrl.zip	Edgar Link	pending
exhibit311-ceocertific.htm	Edgar Link	pending
exhibit312-cfocertific.htm	Edgar Link	pending
exhibit321-ceocertific.htm	Edgar Link	pending
exhibit322-cfocertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
kids-20200331.htm	Edgar Link	pending
kids-20200331.xsd	Edgar Link	pending
kids-20200331_cal.xml	Edgar Link	unprocessable
kids-20200331_def.xml	Edgar Link	unprocessable
kids-20200331_htm.xml	Edgar Link	completed
kids-20200331_lab.xml	Edgar Link	unprocessable
kids-20200331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KIDS
OrthoPediatrics Corp Stock $kids

2020 Q1 Form 10-Q Financial Statement

#000142545020000043 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS OrthoPediatrics Corp Stock $kids

2020 Q1 Form 10-Q Financial Statement

#000142545020000043 Filed on May 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KIDS
OrthoPediatrics Corp Stock $kids